Kb): (616

The search for a "616 KB" article points directly to a significant medical study titled

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies . (616 KB)

: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications

This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort The search for a "616 KB" article points

: Finding ways to help patients manage side effects so they can stay on the therapy longer.

: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). : Both groups had roughly the same time

The study highlighted a few differences between "real-world" patients and those in trials: